Tag: MENA

Posted on

ZRG Global Talent Advisory Establishes Presence in Dubai

DUBAI, United Arab Emirates, Oct. 24, 2022 (GLOBE NEWSWIRE) — ZRG, a New Jersey-based global talent advisory firm, has established a critical presence in Dubai, UAE. With this office, the firm now has team members positioned in key global markets on five continents. The office will be led by Natalie Sleiman, Managing Director and EMEA Lead for the firm’s Professional & Technology Services practice.

Following successful expansion in South America, Europe, the UK, and Australia, ZRG is now positioned to deliver their tech-enabled analytic suite of talent management solutions to the Gulf region.

“Dubai is a crucial financial and cultural hub,” said Larry Hartmann, CEO of ZRG. “Our team here is ready to deliver ZRG’s data driven talent advisory service to clients in the Middle East, Africa, and Asia, alongside our colleagues in the Americas, Europe, and Australia.”

ZRG’s expanded service offerings include Organizational Culture Assessment, Consulting and transformation through their Walking the Talk division. Their Brimstone Consulting division further adds leadership alignment and acceleration, bringing clients an end-to-end talent solution. The company also serves clients in over two dozen industry and functional practices, including media, sports and entertainment powerhouses, TurnkeyZRG and Sucherman Group.

“Natalie Sleiman brings an outstanding record of leadership in the tech sector to ZRG. Her knowledge of the business landscape of the Middle East will help our clients worldwide as we build in this vital market,” said Abe Doctor, Managing Partner and Global Professional & Technology Services Practice Group Leader.

“Our Dubai office has deep expertise in numerous industry verticals,” adds Sleiman. “Cross-border, cross-industry, and cross-cultural collaboration are all part of what makes ZRG special, and we’re eager to serve our clients talent needs here and across the globe.”

The firm celebrated its new presence in Dubai International Financial Center with a grand opening reception at the Capital Club on October 24.

About ZRG
ZRG is a global talent advisory firm that is changing the way companies hire and manage talent. ZRG’s data-driven approach to executive and professional search has been changing the way clients think about how to find top talent. The company’s digital Zi platform combines talent intelligence, candidate insights, and process improvement to dramatically deliver executive searches quicker and with proven better results.

Today, with the help of private equity investor RFE Investment Partners, ZRG is among the fastest growing firms in the search industry and provides a full suite of retained search, on-demand talent, and consulting and advisory solutions across the Americas, Asia, Europe, and Australia.

Contact: John Mooney, Over The Moon PR, (908) 720-6057, john@overthemoonpr.com

GlobeNewswire Distribution ID 8681315

Posted on

Nyxoah Announces Change to Board of Directors

Nyxoah Announces Change to Board of Directors

Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
[email protected]
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
[email protected]
+1 917 749 1494

Attachment

GlobeNewswire Distribution ID 1000752682

Posted on

BioCell Technology Expands Global Presence and Trust with Prestigious Halal Certification

BioCell Collagen®, the company’s flagship ingredient, is now halal-certified by the Islamic Information Documentation and Certification GmbH (IIDC), an accreditation accepted in nearly all Islamic countries

IRVINE, Calif., Oct. 25, 2022 /PRNewswire/ — BioCell Collagen®, a clinically-studied dietary supplement ingredient with more than twenty years of safe and effective use, is now recognized as halal-certified by the Islamic Information Documentation and Certification GmbH (IIDC). This prestigious certification is accepted in nearly all Islamic countries, including the most rigorous in standard, expanding the global reach and availability of BioCell Collagen®.

BioCell Collagen® is now recognized as halal-certified by the Islamic Information Documentation and Certification GmbH (IIDC).

For those seeking top-quality halal-certified products, including the 1.6 billion Muslims in the world, this certification provides consumers with transparency and trust in BioCell Collagen®.

“The halal product category is growing, and more consumers are looking for the IIDC halal symbol as it affirms the product’s commitment to safety and health,” said Mohammed Ishaq, CEO of BioCell Technology. “It’s important to us to reach and serve those who seek halal-certified products, and BioCell Collagen® meets those strict standards.”

Collagen ingredients are complex and various methods need to be used to characterize the quality of the ingredient at the supply level. BioCell Collagen® is produced according to halal standards recognized by the globally renowned standard of IIDC and all aspects of production are permissible according to Islamic law.BioCell Collagen Logo

BioCell Collagen® is one of the few science-backed dietary supplement ingredients that addresses the physiological degradation of connective tissue and the associated age-related loss of their structurally essential molecules. More than a decade of research, including seven human clinical trials, shows that BioCell Collagen® can significantly combat visible signs of aging, such as wrinkles, fine lines and crow’s feet, while providing internal support for healthy connective tissues and joints. This is achieved as a result of BioCell Collagen’s unique synergistic ingredient composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate, and hyaluronic acid. This unique composition sets BioCell Collagen® apart from other collagen supplements.

“With this new specification, we look forward to supporting more consumers who want more youthful-looking skin, active joints and healthy connective tissue as they incorporate BioCell Collagen® into their daily dietary supplement and nutrition routines,” said Ishaq.

BioCell Collagen® is available as a stand-alone product or as a primary ingredient in hundreds of formulations worldwide from leading dietary supplement brands.

The IIDC is an independent and internationally accredited inspection and certification center for halal foods and services, officially recognized by numerous prestigious organizations, including Saudi Food & Drug Authority, United Arab Emirates, The Central Islamic Council of Thailand, JAKIM Malaysia and HAK Turkey.

For more information, please visit BioCell Technology. BioCell Technology executives will be at SupplySide West in Las Vegas, booth #3657, and Health Ingredients in Paris, booth #7.2N44.

About BioCell Collagen®
BioCell Collagen® is a clinically tested branded dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials, including trials on safety, efficacy, and bioavailability. BioCell Collagen® is self-affirmed GRAS (Generally Recognized As Safe). BioCell Collagen® is non-GMO and free of gluten, soy, shellfish, fish, egg, milk, peanuts and sugar. BioCell Collagen® is made exclusively in the USA and Germany. For more information, visit www.BioCellCollagen.com.

About BioCell Technology, LLC
BioCell Technology is a research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information, visit www.BioCellTechnology.com.

Photo – https://mma.prnewswire.com/media/1927521/BioCell___Halal_Combined_FINAL.jpg

Logo – https://mma.prnewswire.com/media/1159802/BioCell_Collagen__Logo.jpg

Posted on

Taconic Biosciences Launches First and Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors, for Improved Antibody Therapy Assessment

FcResolv™ NOG Models Provide Greater Clarity and More Translatable Data

RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv™ NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcγRs) known to confound results in antibody-based therapy studies.

Murine FcγRs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery. FcResolv NOG models knock out these receptors for greater clarity in antibody-based drug studies, affording investigators greater confidence and more translatable data with fewer studies and fewer animals. With applicability in oncology, immuno-oncology, and autoimmune disease, FcResolv NOG models are suitable for engrafting a wide range of human cells and tissues, including simultaneous human tumor engraftment and immune system humanization.

“Antibody-based therapies represent one of the fastest-growing classes of drugs, creating a pressing need for better preclinical tools to assess therapeutics such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies,” said Dr. Michael Seiler, vice president of commercial products at Taconic. “Taconic’s FcResolv NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptor activity.”

FcResolv NOG models eliminate the false negatives that occur when an antibody-based therapeutic’s Fc domain interacts with murine FcγRs as well as the false positives that result when FcγRs trigger residual murine immune activity. They also eliminate costly deconvolution steps otherwise needed to distinguish true drug efficacy from off-target effects mediated through the mouse immune system. With more reliable answers, researchers can target their drug discovery investments more strategically and effectively.

The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse®. The portfolio currently includes two models:

  • FcResolv NOG, for tumor xenografts using cell lines or patient-derived tumors, engraftment of other normal or pathological human cells and tissues, and immune system humanization studies
  • FcResolv hIL-15 NOG, which supports engraftment of human NK cells and is suitable for efficacy studies on antibody-based therapeutics with an antibody-dependent cellular cytotoxicity (ADCC) mechanism of action

To learn more about the FcResolv NOG portfolio, visit www.Taconic.com/fcresolv. Or call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email [email protected].

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Louise Baskin, Senior Director New Product Pipeline

303-432-2495

[email protected]

GlobeNewswire Distribution ID 8670208

Posted on

Eurora partners with DPDgroup to automate cross-border trade compliance

TALLINN, Estonia, Oct. 24, 2022 (GLOBE NEWSWIRE) — Eurora Solutions, the provider of a leading AI/ML (artificial intelligence/machine learning) backed cross-border trade compliance platform, launches a partnership with DPDgroup, one of the world’s leading parcel delivery network. 

This partnership will enable DPDgroup, which delivers 2.1 billion parcels yearly, to enhance its quality and compliance processes whilst lowering the costs of customs processing.

DPDgroup will use Eurora’s AI/ML-backed platform to automate the allocation of product classification (HS) codes and compliance with the export control rules applied in the European Union, the United Kingdom, and the United States. The allocation of product classification (HS) codes and export control classification (ECCN code) is a pivotal step within the export process, as these classifications are needed to prove all restrictions and license requirements have been duly checked by the shipper before exporting an item.

Eurora’s compliance platform processes up to 5,000 requests per second with 98% accuracy* – the highest level of accuracy, speed, and automation available in the market. As there are more than 15,000 10-digit commodity codes in the EU alone, it is impossible to match this speed and cost with manual or hybrid methods, most used today.

As a next step, both companies are looking towards extending the geographical coverage of export compliance services, namely to the Middle East and Asia.

“Eurora and the DPDgroup have been closely working together since the beginning of 2022 to elaborate the rules of different jurisdictions, containing a wide range of classification rules and restrictions that have been ´learned´ by the Eurora machine,” said Marko Lastik, founder and Group CEO of Eurora.

DPDgroup, delivering over 8.4 million parcels worldwide each day, was looking for a solution that would enhance its parcel delivery operations. “In a context where product safety and transport security processes are key, and with growing international activity, we always aim to enhance quality and compliance. Using AI and Machine Learning solutions will help us improve the scalability and reliability of our international operations, while paving the path for future opportunities like new customer services, new geography, and further automation,” said Olivier Tsalpatouros, Senior Director Regulatory & Global Trade Affairs at DPDgroup.

“Years of scientific research and developing machine learning capabilities have allowed Eurora to demonstrate that we are trusted by the logistics and postal industry. Eurora AI engine can find the most appropriate response from a large amount of data by learning from constantly adding data,” Marko Lastik explained.

Eurora’s AI uses over 500 million records of training data from real transactions of the world’s largest logistics service providers. The platform can be used by online sellers, marketplaces, logistics and postal companies to automate tax and duty declarations and assign the appropriate HS code.

*Level observed on Eurora’s overall compliance platforms solutions in 2022.

Photos: Please use the link here to access photos, videos and logos of DPD and Eurora co-operation.

About GeoPost/DPDgroup

DPDgroup is one of the world leading parcel delivery networks, aiming to be a reference in sustainable delivery and become a leading enabler of e-commerce acceleration. We combine innovative technology and local knowledge to provide a flexible and user-friendly service for both shippers and shoppers.

With 120,000 delivery experts operating in nearly 50 countries, and a network of 70,000 Pickup points, DPDgroup delivers 8.4 million parcels worldwide each day – 2.1 billion parcels per year – through the brands DPD, Chronopost, SEUR, BRT and Jadlog. DPDgroup is the parcel delivery network of GeoPost. GeoPost posted sales of €14.7 billion in 2021.

About Eurora Solutions

Eurora uses artificial intelligence and machine learning to automatically manage cross-border VAT, duty amounts, and declarations.

In recent months, Eurora has opened a UK Central office in London and a US Central office in Miami. Chris Lentjes, a Pitney Bowes and DHL veteran with more than 20+ years of industry experience, became Eurora’s US CEO; e-commerce heavyweight Walter Trezek joined Eurora as the Non-Executive Chairman of the Supervisory Board.

Eurora was founded in 2018 by Marko Lastik, a global logistics expert with over 30 years of experience, most of it connected with Asia. Eurora employs over 165 people in 18 countries.

For more information:
Mari-Liis Kitter
Press Contact [email protected]

GlobeNewswire Distribution ID 1000752544